The UK Bribery Act (UKBA) puts particular pressure on pharmaceutical companies. Already operating in a highly regulated environment, due to the nature of their business pharma companies are active and associate with third parties in various locales around the world, and often have many bureaucratic hurdles to overcome. This paper discusses the particular vulnerabilities of the industry in light of the UKBA.